Literature DB >> 22891183

Genetic testing for respiratory disease: are we there yet?

Peter D Paré1.   

Abstract

The human genome project promised a revolution in health care - the development of 'personalized medicine', where knowledge of an individual's genetic code enables the prediction of risk for specific diseases and the potential to alter that risk based on preventive measures and lifestyle modification. The present brief review provides a report card on the progress toward that goal with respect to respiratory disease. Should generalized population screening for genetic risk factors for respiratory disease be instituted? Or not?

Entities:  

Mesh：

Year:  2012        PMID： 22891183      PMCID： PMC3411388          DOI： 10.1155/2012/212658

Source DB:  PubMed          Journal:  Can Respir J        ISSN： 1198-2241            Impact factor:   2.409


  5 in total

1.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

2.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

Review 3.  Advances in treatment of lung cancer with targeted therapy.

Authors:  Philip T Cagle; Lucian R Chirieac
Journal:  Arch Pathol Lab Med       Date:  2012-05       Impact factor: 5.534

Review 4.  Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.

Authors:  Johannes Oldenburg; Carville G Bevans; Andreas Fregin; Christof Geisen; Clemens Müller-Reible; Matthias Watzka
Journal:  Thromb Haemost       Date:  2007-09       Impact factor: 5.249

5.  A large-scale, consortium-based genomewide association study of asthma.

Authors:  Miriam F Moffatt; Ivo G Gut; Florence Demenais; David P Strachan; Emmanuelle Bouzigon; Simon Heath; Erika von Mutius; Martin Farrall; Mark Lathrop; William O C M Cookson
Journal:  N Engl J Med       Date:  2010-09-23       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.